Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18475393 | 1.00 | CTSD (0.51) | CTSDKMT2AHSD17B10DHODHPOLB | |
| SCHEMBL25920599 | 0.86 | TSHR (0.52) | KMT2AHSD17B10POLBTSHRRECQL | |
| SCHEMBL17839814 | 0.85 | PTPN1 (0.45) | KMT2AHSD17B10POLB | |
| SCHEMBL18445963 | 0.85 | CYP1A2 (0.49) | KMT2AHSD17B10POLBTSHRRECQL | |
| SCHEMBL29453449 | 0.85 | PTPN1 (0.45) | KMT2AHSD17B10POLB | |
| SCHEMBL17839574 | 0.85 | PTPN1 (0.45) | KMT2AHSD17B10POLB | |
| SCHEMBL29453445 | 0.85 | PTPN1 (0.45) | KMT2AHSD17B10POLB | |
| SCHEMBL18493737 | 0.85 | HSD17B10 (0.48) | KMT2AHSD17B10POLBTSHRALDH1A1 | |
| SCHEMBL24172945 | 0.84 | PTPN1 (0.46) | KMT2AHSD17B10POLBMEN1 | |
| SCHEMBL20934599 | 0.83 | LMNA (0.57) | KMT2AHSD17B10POLBTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024317-A2 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |